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Abstract
Purpose of Review Type 2 diabetes (T2DM) presents a growing global health and economic burden. Dental settings have been
employed to identify individuals who may be at high risk of diabetes, who exhibit non-diabetic hyperglycaemia (NDH – also
termed “prediabetes”) and who already unknowingly have the condition, through the use of targeted risk-assessments. This
review aims to synthesize the existing literature supporting dental teams’ identification of individuals at an increased risk of or
suffering from undiagnosed NDH or T2DM in dental specialist care settings.
Recent Findings Electronic databases were searched for studies reporting the identification of NDH and or T2DM, in specialist
care dental settings. Screening of returned articles and data extraction were completed by two independent reviewers (RJ, ZY). A
descriptive synthesis of the included articles was undertaken. Due to heterogeneity of the literature, a meta-analysis could not be
performed. The search yielded 52 eligible studies, of which 12 focused primarily on stakeholder opinions. Opinions of patients,
dentists, dental hygienists, dental students and physicians on case identification of T2DM by oral health professionals were
generally positive. The main barriers cited were time, cost, inadequate training and low follow-up of participants by primary care
physicians. The risk assessment processes varied, with most studies using a combination of methods consisting of a questionnaire
followed by a chairside blood sample. Methods utilizing questionnaires, gingival crevicular blood (GCB), fingerstick blood
(FSB) and urine samples have all been evaluated.
Summary This review demonstrates that there may be benefit in engaging the dental workforce to identify cases of NDH and
undiagnosed T2DM and that such a care pathway has the support of multiple stakeholders. Further high-quality research is
required to assess both the clinical and cost-effectiveness of such practice in order to optimize protocols and patient care
pathways. Studies should include a comparison of methods, health economic analyses and protocols to ensure those identified
as high-risk go on to receive appropriate follow-up care.
Keywords Type 2 diabetes . Non-diabetic hyperglycaemia . Screening . Risk assessment . Dental settings
Introduction
Type 2 diabetes mellitus (T2DM) is a growing public health
concern, affecting approximately 60 million people in Europe,
which equates to 10% of those aged over 25 years. More than
422 million adults are living with the condition globally ac-
cording to the World Health Organization [1]. In 2017, 1 in 2
people (212 million individuals in total) were living with undi-
agnosed T2DM [2]. Additionally, many individuals with
T2DM may remain undiagnosed for many years due to
T2DM being asymptomatic in its early stages. This has impli-
cations for the secondary prevention and management of the
condition [2]. Therefore, there is merit in exploring non-
This article is part of the Topical Collection onHost Parasite Interactions
in Periodontal Disease
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s40496-020-00250-w) contains supplementary
material, which is available to authorized users.
* Iain Chapple
I.L.C.CHAPPLE@bham.ac.uk
1 Periodontology Research Group, School of Dentistry, Birmingham
Dental Hospital, University of Birmingham, Birmingham, UK
2 The Eastman Dental Hospital, London, UK
3 Department of Health Sciences, University of Leicester,
Leicester, UK
4 Institute of Clinical Sciences, College of Medical & Dental Sciences,
The University of Birmingham, Birmingham, UK
Current Oral Health Reports
https://doi.org/10.1007/s40496-020-00250-w
traditional approaches to enhance early identification of indi-
viduals with non-diabetic hyperglycaemia (NDH) and undiag-
nosed T2DM.
NDH or impaired glucose regulation refers to elevated
blood glucose levels that are not yet in the diabetes range. In
addition to an increased risk of T2DM, individuals with NDH
are also at increased risk of developing cardiovascular condi-
tions [2]. By identifying NDH early, it can aid in the primary
prevention of T2DM. The International Diabetes Federation
reported that in 2017 over 325 million people were at high risk
of developing T2DM. These people are classified as having
NDH or prediabetes [3].
The Global Burden of Diseases, Injuries, and Risk Factors
Study 2017 (GBD 2017) reported that from 1990 to 2017, oral
diseases (mainly periodontitis and caries) contributed the most
years lost due to disability (YLD) in age-standardized preva-
lence rates from 354 diseases and injuries across 195 countries
[4•]. Severe periodontitis affects 11.2% of adults worldwide
[5]. Milder forms are even more prevalent, affecting 50% of
adults and 60% of individuals over the age of 65. Importantly,
severe periodontitis is significantly and independently associ-
ated with T2DM [6•, 7–9]. Furthermore, glycaemic status di-
rectly impacts oral health [10]. Poor glycaemic control brings
unwelcome consequences for periodontal health which ulti-
mately, if left untreated, may lead to tooth loss and associated
psychosocial sequelae [6•, 11–18]. Due to the well-established
bidirectional relationship between periodontitis and T2DM,
improvements in periodontal status can lead to improvements
in diabetes control [6•, 9, 18–23], as evidenced by a recent
randomized control trial which demonstrated a 0.6% reduc-
tion in HbA1c at 12 months among patients who had received
intensive periodontal therapy [24]. Screening for periodontitis
is an established and mandatory procedure within dental set-
tings in many countries around the world, providing informa-
tion on oral risk factors for diabetes that primary care physi-
cians are unable to assess.
In addition to the human cost of diabetes and periodontitis,
and associated morbidity and mortality, there is a significant
economic burden associated with both diseases. Severe peri-
odontitis is estimated to cost $54 billion (US dollars or USD)
per year globally in lost productivity [25]. Periodontitis is also
a major contributor to the aggregate direct treatment costs of
oral disease, estimated at $91.05 billion (USD) for western
Europe and $297.67 billion (USD) worldwide in 2010.
These were considerably higher when aggregated with indi-
rect costs, amounting to $442 billion (USD) [26].
It is in the interests of dental teams to know whether their
patients have NDH or undiagnosed T2DM, due to the impact
of both upon periodontal stability and treatment outcomes.
Given the inter-relationship between these two chronic, non-
communicable diseases, raising awareness of the NDH/
T2DM status of patients in the dental environment will enable
dental teams to better target their prevention and management
strategies to improve oral health. Moreover, earlier detection
of both conditions will facilitate improved systemic health
outcomes for these individuals by facilitating appropriate pre-
vention and interventions, further demonstrating the role that
dental teams can play in assisting with management of the
growing health and economic burden of T2DM.
Aims and Objectives
The objective of this review is to synthesize current evidence
supporting dental teams’ identification of individuals at an
increased risk of or suffering from undiagnosed NDH or
T2DM in dental specialist care settings. Evidence evaluated
includes the opinions of key stakeholders, barriers to and fa-
cilitators of subject identification and the clinical methods
used.
Materials and Methods
The present study was undertaken using a pre-specified pro-
tocol and reported according to the “Preferred Reporting Items
for Systematic Reviews and Meta-Analyses” (PRISMA)
guidelines for conducting and reporting systematic reviews
and meta-analyses [27].
The Population, Intervention, Reference standard, Target
condition (PIRT) format was followed for this reviewwhereby
[P] were stakeholders in the delivery of dental care, including
patients aged greater than 18 years attending dental services,
healthcare professionals and organizations involved in the de-
livery of dental care, [I] were the described screening modal-
ities, [R] was the method by which NDH or T2DM was diag-
nosed and [T] was NDH or T2DM.
Inclusion Criteria
The inclusion criteria for the study included articles which met
the following criteria:
– Risk assessment for NDH/ T2DM was undertaken in a
hospital or specialist care dental setting.
– Opinions of stakeholders relating to diabetes risk assess-
ment in dental settings were sought.
– Study subjects were adults (> 18 years of age).
– The article was written in the English language.
Search Strategy
Electronic bibliographic databases were searched, including
MEDLINE, PubMed, the Cochrane Library, Clinicaltrials.
gov and Web of Science. The reference lists of all eligible
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full texts were searched for additional papers. The search
strategy (Table 1) included terms relating to or describing
the identification of NDH or T2DM in dental settings. The
search terms were adapted for use with other bibliographic
databases. Restrictions to English language were applied and
searches were limited to dates between January 1950 and
October 2019.
Data Extraction and Management
The titles and abstracts of all returned papers were screened
for the inclusion criteria. For included papers, full texts were
reviewed, and any further exclusions determined by consen-
sus. Reasons for exclusion at the full-text stage were recorded
(Fig. 1). Electronic data extraction forms were developed,
piloted and employed for all data extraction.
Strategy for Synthesis
It was anticipated that included studies would be highly het-
erogenous, resulting in a descriptive analytical approach. The
descriptive synthesis was structured around the objectives of
this review.
Risk of Bias Assessment
Two independent reviewers (ZY and JB) assessed the articles
describing screening undertaken in a dental setting. Quality of
the papers was assessed using a published and validated risk
of bias assessment tool, the “United States Preventative Task
Force Criteria for Assessing Internal Validity of Individual
Studies”.
Results
The search strategy yielded 52 papers to be included. Eleven
studies were focused on stakeholder opinion. Twenty-eight
studies were primarily focused on undertaking risk assess-
ments. The remaining studies had multiple elements including
risk assessment and recording of stakeholder opinions.
The risk of bias assessment (Supplementary Table 2) dem-
onstrated acceptable concordance between the two indepen-
dent examiners (ZYand JB) with a kappa of 0.75.Where there
was disagreement in initial quality grade (n = 9), this was re-
solved through discussion and consensus in each case. The
majority of articles were deemed to be of good quality, dem-
onstrating a low risk of bias (n = 18). Seventeen articles
showed a moderate risk of bias and one article was deemed
to have a high risk of bias.
Eleven of the returned articles primarily focused on the
opinions, attitudes and perceptions of stakeholders. Of these,
five articles were related to patient perception, two to dental
provider perceptions and the remaining four to dental hygien-
ists, dental students, physicians and “authorities and organiza-
tions” (Table 2).
Among studies that asked patients whether they felt it was
“important” that dentists identify individuals at high risk of
T2DM, patient support was strong, in a range of 73%–87%
[33, 35, 36, 39–41]. In addition to this acknowledgement,
most patients surveyed were willing to undergo chairside
screening methods that yielded immediate results and discuss
the results of such tests with their dentist [35, 36, 39, 40].
In support of the positive patient opinion, one study report-
ed that more than 60% of dentists surveyed believed that ad-
dressing T2DM was important to their role as a dentist, while
86% claimed to advise their patients with T2DM about their
increased periodontal risk and 18% reported that they provid-
ed additional diabetes-related services [29]. Two-thirds of
dentists in another study stated they would be interested in
performing blood glucose monitoring if the costs were reim-
bursed [31]. A further study assessing the views of dentists
reported that most felt it was important to conduct screening
for diabetes (76%), and 96% of respondents were willing to
refer patients to a primary care physician for consultation.
When methods of risk assessment were discussed, the major-
ity were happy to collect oral fluids for salivary diagnostics
(88%) or conduct medical screening that yielded immediate
results (83%). The respondents in this particular study were
significantly more willing to collect saliva than record height
and weight measurements or undertake FSB collection.
“Insurance” was also significantly less important to the den-
tists compared to time, cost, liability or patients’ willingness
[29].
In addition to the qualified dental workforce, one study
sought the opinion of dental students to determine their opin-
ions and willingness to assess patients for NDH/ T2DM.
Table 1 Search strategy:
example of search
strategy used in PubMed
Search terms used
(Screening[Title/Abstract] OR “risk
assessment”[Title/Abstract] OR “case
detection”[Title/Abstract] OR “case
finding”[Title/Abstract] OR “case
identification”[Title/Abstract] OR “risk
detection”[Title/Abstract] OR
diagnosis[Title/Abstract])) AND
(diabetes[Title/Abstract] OR
TTDM[Title/Abstract] OR T2DM
[Title/Abstract] OR
diabetic[Title/Abstract] OR
pre-diabetes[Title/Abstract] OR
prediabetes[Title/Abstract] OR
NDH[Title/Abstract] OR
hyperglycaemia[Title/Abstract] OR
hyperglycemia[Title/Abstract] OR
dysglycaemia[Title/Abstract] OR
dysglycemia[Title/Abstract])) AND
(dental[Title/Abstract] OR
dentistry[Title/Abstract] OR
dentist[Title/Abstract])
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There was a high acceptability (84%) for FSB collection
among dental students. The key factor for their acceptance
was appropriate training in the required techniques [28].
In a single study reflecting opinions of dental hygienists,
85% stated theywere willing to conduct screening that yielded
immediate results. Ninety-four percent of dental hygienists
surveyed were willing to refer patients for medical consulta-
tion if required. When asked which considerations they felt
were most important, over 97% of respondents stated dentist/
owner support, patient willingness and time and adequate
training [42].
A study of 1508 physicians reported that 71% felt it was
beneficial for dentists to conduct screening for T2DM.
Respondents were willing to discuss results with the dentist
(76%) and accept patient referrals (89%). The majority of
respondents also felt it was unimportant that the medical re-
ferral came from a dentist rather than a physician. The factor
physicians felt most important was patient willingness, and
overall, primary care physicians considered chairside medical
screening in a dental setting to be valuable and worthwhile
[34].
One study of patients and providers identified themes that
arose from the interviews, including “a good chance to
check”, “patient choice” and “a new way of interacting and
viewing the dental visit”. This study suggested that both pa-
tients and dental providers believe that dental visit is an op-
portune situation for diabetes screening.
The principal barriers to undertaking screening for T2DM
in dental settings were time, adequate training, support of the
dentist or dental practice owner and patient willingness.
Interestingly, in one study that assessed the willingness of
racial/ethnic minority older adults to receive hypertension
and diabetes screening as part of routine dental visits, five
key themes emerged. These included that they found chairside
risk assessment to be acceptable, that as older adults they
found screening for conditions by healthcare professionals to
be routine practice, that the interrelationship between oral and
general health was appreciated, and that they perceived benefit
to chairside screening. In some cases, it was also felt that
chairside screening for general health conditions may reduce
dental anxiety [35]. This study also identified key themes
relating to patient-perceived barriers, which included that for
some, dental fear may limit the acceptability of dental teams
conducting chairside screening. Additional themes identified
included that given the routine nature of screening for this
demographic that there was a perceived lack of need for dental
care and chairside screening in addition to a mistrust of dental
providers as primary care providers among some of the sam-
ple [35].
Another concern cited was the poor follow-up rates with
primary care medical practitioners. Poor follow-up was attrib-
uted to barriers including patients’ inadequate knowledge
about diabetes, lack of understanding about the importance
of follow-up, “general business”, financial concerns, fear
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Fig. 1 PRISMA flow diagram for
filtration of the search results
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Table 2 Summary of journal articles exploring stakeholder perceptions, attitudes and opinions to screening for diabetes in dental settings
Paper Reference Year Country Stakeholder Key finding (Barriers and facilitators) key-findings
Anders et al. “Dental students’ glucometer
experience and attitudes toward diabetes
counselling, monitoring, and screening: a
comparative study.”
[28] 2014 USA Dental students Dental students’ attitudes toward T2DM
counselling, monitoring and screening were
generally positive and more positive for those
students who had greater experience using a
glucometer. A high acceptance rate (84%) for
FSB among dental personnel who had hands-on
experience using a glucometer was reported.
Esmeili et al. “Dentists’ attitudes and
practices related to diabetes in the dental
setting.”
[29] 2009 USA Dentists Sixty-one percent of respondents believed that
addressing T2DM was important to their role,
86% advised patients with T2DM about
periodontal risks, 18% provided T2DM-related
services, 47% reported they knew how to assess
for diabetes, and 42% felt well prepared to
intervene with patients with diabetes. 66% of
dentists reported interest in performing blood
glucose monitoring if it was reimbursed.
Friman et al. “Medical screening in dental
settings: a qualitative study of the views
of authorities and organizations.”
[30] 2015 Sweden Authorities &
organization
Approached authorities and organizations generally
had a positive view of medical screening in
dental settings but were uncertain about the
concept. Further scientific knowledge and
guidelines concerning the topic are needed
before it can be commonly introduced, alongside
additional research on implementation strategies
and long-term follow-up.
Greenberg et al. “Dentists’ attitudes toward
chairside screening for medical
conditions.”
[31] 2010 USA Dentists The majority thought it was important for dentists
to conduct screening for T2DM (76.6%).
Respondents were willing to refer patients for
consultation with physicians (96.4%), collect
oral fluids for salivary diagnostics (87.7%),
conduct medical screenings that yield immediate
results (83.4%) and collect blood via FSB
(55.9%). Respondents were significantly more
willing (P < .001) to collect saliva than height
andweight measurements or FSB. Insurance was
significantly less important (P < .001) than time,
cost, liability or patients’ willingness.”
Greenberg et al. “American dental
hygienists’ attitudes toward chairside
medical screening in a dental setting.”
[32] 2016 USA Dental hygienists Given that dental hygienists are involved in
preventive and educational activities, medical
screening seems like a natural extension to their
roles. The majority of respondents (89%) felt it
was important to perform chairside screening for
T2DM. Majorities were also willing to refer a
patient for medical consult (94%), conduct
screening that yields immediate results (85%)
and to collect data/samples needed (57%–95%).
The most important considerations were
dentist/owner support (98%), training (97%),
patient willingness (98%) and time (98%).
Greenberg et al. “Patients’ attitudes toward
screening for medical conditions in a
dental setting.”
[33] 2012 USA Patients The majority of respondents were willing to have a
dentist conduct screening for medical conditions
with 73% specifically open to T2DM screening.
The majority of clinic and private practice
respondents were willing to let the dentist
conduct screening that yields immediate results
(90% vs 76%), discuss results during their dental
visit (89% vs 79%), refer them for a medical
consult (86% vs 76%) and send samples to an
outside laboratory (76% vs 59%). Among
potential barriers specified, both clinic and
private practice respondents felt confidentiality
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Table 2 (continued)
Paper Reference Year Country Stakeholder Key finding (Barriers and facilitators) key-findings
was important (94% vs 83%) followed by time
(90% vs 80%) and insurance coverage (82% vs
80%). Seventy-six percent of clinic respondents
were willing to pay $10–20, and 65% were
willing to pay $21–30; the percentage who were
willing to pay more than $30 dropped
dramatically.
Greenberg et al. “Physicians’ attitudes
toward medical screening in a dental
setting.”
[34] 2015 USA Physician Of 1508 respondents, the majority felt it was
valuable for dentists to conduct screening for
T2DM (71%). Respondents were willing to
discuss results with the dentist (76%) and accept
patient referrals (89%), and a small majority felt
it was unimportant that the medical referral came
from a dentist rather than a physician (52%). The
most important consideration was patient
willingness (mean rank 2.55). Primary care
physicians considered chairside medical
screening in a dental setting to be valuable and
worthwhile.
Greenblatt et al. “Acceptability of Chairside
Screening for Racial/Ethnic Minority
Older Adults: A Qualitative Study.”
[35] 2017 USA Patients Five themes were manifest in the data regarding the
willingness of racial/ethnic minority older adults
to receive hypertension and T2DM screening as
part of routine dental visits: (1) chairside
screening is acceptable, (2) screening is routine
for older adults, (3) the interrelationship between
oral and general health is appreciated, (4)
chairside screening has perceived benefits, and
(5) chairside screening may reduce dental
anxiety.Reservations centred on four major
themes: (1) dental fear may limit the
acceptability of chairside screening, (2) there is a
perceived lack of need for dental care and
chairside screening, (3) screening is available
elsewhere, and (4) mistrust of dental providers as
primary care providers.
Sansare et al. “Indian patients’ attitudes
toward chairside screening in a dental
setting for medical conditions.”
[36] 2015 India Patients A survey given to a convenience sample of adult
patients visiting five university-based dental
clinics (clinic group) and one private practice
showed that both patient groups felt it was
important for dentists to identify increased risk
for medical conditions. The majority of patients
were willing to have a dentist screen for specified
conditions including T2DM (84.5% clinic and
77.5% private). The majority of patients were
willing to participate in chairside screening that
yielded immediate results and discuss results
immediately.
Scambler et al. “Summary of: Patients’
attitudes toward screening for diabetes
and other medical conditions in the dental
setting”
[37] 2014 UK Patients A self-administered questionnaire distributed to
adult patients (≥ 18 years) attending 2 primary
care dental clinics and 16 general dental practices
in South West England. Overall, 87% of
respondents thought that it was important or very
important that dentists screened patients for
medical conditions such as T2DM; 79% were
very willing to let a dental team member carry
out screening. Significantly higher proportions
of respondents in the primary care clinics
indicated willingness compared to general
practices. Nearly two-thirds of primary care
clinic respondents and over half of general
practice patients indicated that they would be
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and denial [38]. Only 53% of participants with elevated
HbA1c values contacted their primary medical healthcare pro-
vider within 2 weeks as recommended in a pilot study [43].
Though a UK-based team also found that following up with a
primary medical care provider was a potential barrier, they
reported that patients were three times as likely to contact their
general practitioner (GP) if they had received two positive
screening results when compared with a patient with only
one positive result [44]. A Swedish study with a 3-year fol-
low-up of patients found that 89% had attended their
healthcare provider within that time frame and that 9% of
those had been formally diagnosed with T2DM. The study
also identified that of those who had screened negative,
80.5% attended the primary healthcare centre, and eight
(0.6%) were found to have T2DM. Screening sensitivity was
52.9%, and specificity was 90.6% with positive predictive
value of 5.8%. According to this study, when the population
is limited to those 40–75-year-olds with a BMI > 25 kg /m2
and 30-to 75-year-olds with a BMI > 30 kg /m2, the number
needed to screen was 96 [45].
Twenty-eight articles returned from the search involved
dental teams undertaking various screening methods within
a specialist dental care setting (Supplementary Table 1). The
majority of these studies (n = 10) employed a combination of
screening methods, most commonly questionnaire followed
by FSB sample collection. Within the literature, a range of
screening methods were explored including questionnaires
alone (n = 1), questionnaire in addition to another test
modality (n = 6), FSB collection alone (n = 4), FSB in addition
to another risk assessment modality (n = 11) and GCB collec-
tion (n = 6). Where blood samples were recorded, this was
HbA1c in ten cases (Supplementary Table 1).
Discussion
Principle Findings
Opinions of Key Stakeholders
Overall the opinions of stakeholders relating to dental teams’
engagement in risk assessment of patients for NDH/T2DM
were positive. Furthermore, among patients there was strong
support for tests which were able to yield immediate results.
These findings appeared to transcend specific healthcare sys-
tems and cultural barriers, as similar results were reported
irrespective of their being conducted in different countries
with different models of healthcare provision, including
state-funded healthcare systems in Europe [39–41],
insurance-based and private healthcare within the USA [33]
and university-based clinics and private settings in Asia [36].
Amongmethodologies currently in use, there was a general
preference for GCB instead of FSB collection. GCB testing
was well-tolerated among volunteers and was deemed both
convenient and acceptable to patients. Additionally, it was
Table 2 (continued)
Paper Reference Year Country Stakeholder Key finding (Barriers and facilitators) key-findings
willing to discuss test results with the dental
team. Overall, 61% had never knowingly been
screened or tested for T2DM; 20% reported that
they had been tested within the previous
12 months.
Rosedale et al. “Diabetes screening at the
periodontal visit: Patient and provider
experiences with two screening
approaches”
[38] 2012 USA Patients and provider FSB samples from 120 patients and GCB samples
from 102 of these patients were collected on
special blood collection cards and sent to a
laboratory for HbA1c testing, with test results
sent to the patients from the laboratory.
Quantitative and qualitative data collection and
analyses of patients and providers were
conducted. Themes that arose from the
interviews with providers and patients include “a
good chance to check”, “patient choice”, “FSB
versus GCB testing” and “a new way of
interacting and viewing the dental visit”.
Periodontal patients and dental providers believe
that the dental visit is an opportune site for
T2DM and generally prefer GCB to FSB
collection. GCB testing is well-tolerated,
convenient and acceptable to patients and
reduces time and liability obstacles for dental
providers to conduct T2DM screening.
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found to reduce the obstacles of both time and liability for
dental providers conducting the diabetes screening [38].
The sentiment expressed by patients, that dental teams un-
dertaking risk-assessment for NDH/ T2DM was important,
appeared to be shared by dental service providers [29, 31].
Dental hygienists also play a key role in the delivery of pre-
ventative advice and educational activities in dental practice.
Thus, utilizing this skilled workforce in the delivery of NDH/
T2DM risk assessment appears to be a natural extension of
their current duties, especially given their own strong support
for such an intervention. Another key workforce to consider is
primary care medical practitioners. Should any such addition-
al services commencewithin dental settings, it is of paramount
importance that any duplication of testing and generation of
unnecessary referrals to primary care physicians is minimized.
However, where physician opinion was sought in the litera-
ture, they were in support of the concept of utilizing dental
teams to identify NDH /T2DM.
Given that patients, physicians and dental teams appear to
be in favour of developing the role of the dental team to in-
clude risk-assessment for NDH/ T2DM, it was interesting to
also understand the role of dental undergraduate students.
These students are key to the future delivery of this additional
service. One study based in the USA sought the attitudes of
students toward counselling, monitoring and screening for
T2DM; results were positive provided appropriate training in
the required techniques was provided [28].
Barriers and Facilitators
Several patient-reported barriers and facilitators were identi-
fied within the literature including how the individuals’ per-
ception of dental teams and their own fears and anxiety may
prevent uptake of additional services in such a setting.
However, the patients also reported an appreciation of the
interrelationship between oral and systemic disease and rec-
ognized potential benefit of routine testing by healthcare pro-
fessionals [35].
A further barrier to dental teams undertaking risk assess-
ment for NDH/ T2DM was the poor rate of follow-up with
primary care medical practitioners for appropriate diagnosis
and management. One study reported that while a majority of
patients were interested in T2DM testing in dental offices,
most dentists thought the tests were appropriate and simple
to undertake and that T2DM screening in dental practice was
deemed feasible; poor follow-up by patients, particularly
those tested in private practices was a potential concern re-
quiring further study [46].
In the UK based study that reported improved follow-up
rates where two screening tests were undertaken, the screening
was actually done by a researcher, and there was no analysis of
the practices’ additional workloads or their impact.
Furthermore, the participants were contacted twice by
telephone after their visit by the researcher and asked whether
they had made an appointment with their GP. In many prac-
tices, there may be insufficient staff to undertake such addi-
tional steps, which may impact the outcome and result in an
even further reduced rate of follow-up [44].
The most frequently cited barriers to uptake of new services
were time and cost. Interestingly, a study in the USA found that
the direct cost for each HbA1c test was $9 (USD), excluding
follow-up medical diagnosis. The mean screening time includ-
ing patient education was reported as 14 ± 6.2 min. However,
given the heterogeneity in methods used and devices available
for undertaking each risk assessment method, the costs and
time taken for risk assessment are likely to vary significantly.
Interestingly, one study reported that 76% of patients were
willing to pay $10–20(USD) and 65% were willing to pay
$21–30(USD). However, the percentage of who were willing
to pay more than $30(USD) reduced dramatically [33].
Risk Assessment Methods Used
This systematic review revealed considerable variation in the
methodologies adopted for risk assessing patients in dental
settings for NDH/T2DM. Methods reported in the literature
ranged from applying clinical guidelines and validated risk-
assessment tools to undertaking chairside testing of either
GCB or FSB; urinalysis was also undertaken in some cases.
There are several methodologies accepted for use at each
stage of study design. Screening criteria employed by studies
analysed here were predominantly derived from the recommen-
dations of the American Diabetes Association (ADA) or the
National Institute for Clinical Excellence (NICE). The
American Diabetes Association (ADA) has developed criteria
to classify high-risk patients as being anyone that (I) is over
45 years of age, (II) has a family history of T2DM, (III) has a
BMI > 26 kg/m2, (IV) is sedentary, (V) has hypertension, (VI)
has hyperlipidaemia, (VII) is of a certain racial or ethnic group
(African American or Hispanic), or (VIII) has had gestational
diabetes. The more risk factors an individual has, the higher
their risk of developing diabetes. Many studies have applied
these criteria prior to undertaking a second level of assessment
such as FSB/GCB collection. Similarly, the National Institute
for Clinical Excellence (NICE) guidance exists in the UK [47],
which outlines similar criteria for high-risk individuals and was
used as a “pre-screen” in many of the UK-based studies.
Once a method of study had been determined
(Questionnaire, FSB, GCB collection, urinalysis), there are
still a number of variables that differentiate the protocols of
studies analysed in this review. Accepted “pre-screen”
methods include NICE guidance, ADA criteria and validated
risk-assessment tools such as “FINDRISC”. For a chairside
test following “pre-screen”, either GCB or FSB collection was
employed. Research teams also varied in their biomarker of
choice; most chose to measure HbA1c though some opted for
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random blood glucose tests. No clinical trials exist comparing
the clinical effectiveness and cost-effectiveness of the various
combinations of these methods. Thus, it is difficult to com-
pare, contrast and ultimately decide which protocol offers the
greatest diagnostic accuracy.
Which Risk Assessment Protocol Appears Most Robust
If risk assessment is to be undertaken in dental practices, it
should be targeted to individuals at high risk in order to be time
and cost-effective [2, 48, 49]. Existing evidence demonstrates
that population-based screening is ineffective in terms of cost
and clinical outcome [45]. Therefore, in order to determine
those who may be at high risk, a targeted approach is required.
Local guidelines and geographical location have an influ-
ence on criteria adoption. For example, the ADA criteria are
widely accepted and used across the USA and have been
employed in many of the studies analysed in this review.
NICE guidance suggests that a validated risk assessment tool
such as the “Diabetes UK Risk Score” should be used to
identify individuals at high risk of T2DM. It advocates that
all non-pregnant adults > 40 years of age, members of high-
risk minority ethnic groups (including South Asian, Chinese,
African-Caribbean, black African) aged 25–39 years and any
people with conditions that place them at increased risk of
T2DM should be risk assessed using such validated tools.
Where a score above the threshold is obtained, identifying
an individual as high risk, they should then undergo a blood
test such as HbA1c or fasting plasma glucose [47].
Once a “pre-screen” method has been undertaken to iden-
tify those individuals who may be appropriate for formal risk
assessment, an appropriate screening method must be select-
ed. Currently, the WHO suggests that provided the patient has
symptoms such as polyuria or polydipsia, diagnosis of T2DM
can be based on the following:
& A random venous plasma glucose concentration ≥
11.1 mmol/l
& A fasting plasma glucose concentration ≥ 7.0 mmol/l
(whole blood ≥ 6.1 mmol/l)
& A plasma glucose concentration ≥ 11.1 mmol/l, 2 h after
oral administration of 75 g anhydrous glucose in an oral
glucose tolerance test (OGTT).
Where the patient is asymptomatic, a diagnosis should not
be based on a single glucose determination, but a further con-
firmatory plasma venous blood determination would be re-
quired. At least one additional glucose test result on another
day with a value in the diabetes range is essential, either
fasting, from a random sample or from the 2-h post glucose
load. If the fasting random values are not diagnostic, the 2-h
value should be used. In 2011 the WHO also determined
HbA1c as a suitable method for diagnosing T2DM. They
recommended an HbA1c of 48 mmol/mol (6.5%) as the cut-
off point for diagnosing diabetes. A value of less than
48 mmol/mol (6.5%) does not exclude diabetes diagnosed
when using glucose tolerance tests and that FSB HbA1c
should not be used for diagnosis. Where FSB tests are used,
they must be confirmed by laboratory-based venous HbA1c
test in all patients [1].
In dental settings, the aim is not to diagnose and manage
T2DM but to identify those individuals at high-risk who may
benefit from formal intervention and referral to a physician for
suitable follow-up. The test used must meet these objectives.
Given the potential opportunistic nature of screening in this
setting, OGTTand fasting plasma glucose samples are unlike-
ly to be practical or feasible, leaving HbA1c and random plas-
ma glucose as the remaining viable options.
In 59% of the studies contributing to this reviewwhere some
form of risk assessment was undertaken in a dental setting,
HbA1c was selected as the marker of choice. This was likely
chosen because HbA1c provides a measure of the glucose
bound to haemoglobin and is a reflection of the patient’s glu-
cose control over approximately 90 days. HbA1c has recently
been advocated by the ADA as the “gold standard” test for
screening and diagnosing diabetes, and it does not require the
patient to fast prior to their appointment, making it practical for
use in a dental setting. The decision to be made then is how to
collect the blood sample. Avenous sample collected and sent to
a laboratory, although considered the gold standard, is time-
consuming and costly and potentially requires certain members
of the dental team to undergo additional training. Furthermore,
as evidenced in the literature reporting on patient opinions,
those tests which provided immediate results were most
favoured [33]. Thus, given that chairside HbA1c testing has
been shown to consistently provide results that strongly corre-
late with laboratory assays, and can yield results in as little as
5 min, this may be the preferred option [50].
The two methods of chairside testing covered in the litera-
ture are GCB and FSB collection. Six studies compared GCB
with FSB; the concordance of the two methods was generally
found to be acceptable [51–54]. Some studies reported that
patients may find oral sampling less invasive and more com-
fortable than FSB collection [38], although it was noted that it
is not always feasible to obtain blood from the gingival crevice
[52–55].
Areas for Further Research
Though there is an abundance of literature relating to the use
of dental practices for identifying individuals with NDH/
T2DM, significant further research is required. Specifically,
research into determining the most clinically and cost-
effective methods of risk assessment, with a suitable follow-
up period to determine the proportion of patients who go on to
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receive a formal diagnosis of NDH/T2DMwith a primary care
medical practitioner.
Conclusions
The literature demonstrates that stakeholder opinions, includ-
ing those of patients, dentists, dental hygienists, physicians
and dental students, are all generally positive about the utility
of dental settings to identify individuals who are at high risk of
developing T2DM or who may unknowingly have the condi-
tion. This support crosses healthcare boundaries and has been
explored globally. The primary barriers continue to be related
to time and cost, though concern about poor follow-up of
those individuals highlighted as potentially at-risk was also
noted. The literature is replete with a wide range of available
methodologies for identifying at-risk individuals. It would ap-
pear that a two-staged risk assessment process utilizing a pre-
screen or validated risk score followed by a chairside HbA1c
sample may be most appropriate approach. However, this has
yet to be confirmed by any large-scale clinical trial comparing
different combinations of the myriad of screening methodol-
ogies available. In summary, although some research has been
undertaken to determine opinions and feasibility of utilizing
the dental workforce to risk assess for NDH/ T2DM, further
work is needed to assess both the clinical and cost-
effectiveness of such an approach and to establish clear pro-
tocols and patient care pathways.
Funding Information Thomas Dietrich reports personal fees from Oxtex
Ltd., personal fees from Orthocell, grants from Pfizer, grants from
Dentsply, personal fees from Colgate, personal fees from Laramie, and
grants from Menarini Richerche, outside the submitted work
Compliance with Ethical Standards
Conflict of Interest Zehra Yonel, Joanna Batt, Rosemarie Jane E
Cerullo, Laura J Grey, and Iain Chapple declare that they have no conflict
of interests.
Human and Animal Rights and Informed Consent This article does not
contain any studies with human or animal subjects performed by any of
the authors.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons licence, and indicate if
changes weremade. The images or other third party material in this article
are included in the article's Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in the
article's Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. WHO. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of
DiabetesMellitus: WHO Press; 2011. Contract No.: WHO/NMH/
CHP/CPM/11.1
2. PHE. NHS Diabetes Prevention Programme (NHS DPP) Non-
diabetic hyperglycaemia. London: 2015.
3. Mariano S, Antonio C, Martin B, Iain C. T. DR, Filippo G, et al.
scientific evidence on the links between periodontal diseases and
diabetes: consensus report and guidelines of the joint workshop on
periodontal diseases and diabetes by the international diabetes fed-
eration and the European federation of periodontology. J Clin
Periodontol. 2018;45(2):138–49.
4.• Spencer James CJLM, Vos T, et al. GBD 2017 Disease and Injury
Incidence and Prevalence Collaborators. Global, regional, and national
incidence, prevalence, and years lived with disability for 354 diseases
and injuries for 195 countries and territories, 1990–2017: a systematic
analysis for the Global Burden of Disease Study 2017. Lancet. 392:
1789–858 8 Nov 2018. This reference is considered important as it
highlights the full impact of Oral and Dental disease and how oral
and dental diseases should not be overlooked given the significant
burden in terms of Years Lost to Disability.
5. KassebaumNJ,BernabeE,DahiyaM,BhandariB,MurrayCJ,Marcenes
W. Global burden of severe periodontitis in 1990-2010: a systematic re-
view andmeta-regression. J Dent Res. 2014;93(11):1045–53.
6.• Chapple IL, Genco R, et al. J Periodontol. 2013;84(4 Suppl):S106–
12 This reference is considered important as it was a landmark
manuscript synthesising the evidence relating to Periodontitis
and systemic disease.
7. Izuora K, Ezeanolue E, Schlauch K, Neubauer M, Gewelber C,
Umpierrez G. Impact of periodontal disease on outcomes in diabe-
tes. Contemp Clin Trials. 2015;41:93–9.
8. Garcia D, Tarima S, Okunseri C. Periodontitis and glycemic control
in diabetes: NHANES 2009 to 2012. J Periodontol. 2015;86(4):
499–506.
9. Stanko P, Izakovicova HL. Bidirectional association between dia-
betes mellitus and inflammatory periodontal disease. A review.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.
2014;158(1):35–8.
10. Sanz M, Ceriello A, Buysschaert M, Chapple I, Demmer RT,
Graziani F, et al. Scientific evidence on the links between periodon-
tal diseases and diabetes: Consensus report and guidelines of the
joint workshop on periodontal diseases and diabetes by the
International Diabetes Federation and the European Federation of
Periodontology. J Clin Periodontol. 2018;45(2):138–49This refer-
ence is important as it builds on the previous consensus report
with a particular focus on Periodontitis and Diabetes.
11. Harvey PM. Control of severe periodontitis with reduction of infection
and some recovery of clinical attachment in a patient with initially
undiagnosed diabetes. J N Z Soc Periodontol. 1986;61:12–7.
12. Position Paper; Diabetes and Periodontal Diseases. J Periodontol.
1999;70(8):935–49.
13. Paper P. Diabetes and periodontal diseases. J Periodontol.
2000;71(4):664–78.
14. Al-Khabbaz AK. Type 2 diabetes mellitus and periodontal disease
severity. Oral Health Prev Dent. 2014;12(1):77–82.
15. Artese HP, Foz AM, Rabelo Mde S, Gomes GH, Orlandi M, Suvan J,
et al. Periodontal therapy and systemic inflammation in type 2 diabetes
mellitus: a meta-analysis. PLoS One. 2015;10(5):e0128344.
Curr Oral Health Rep
16. Bascones-Martinez A, Gonzalez-Febles J, Sanz-Esporrin J.
Diabetes and periodontal disease. Review of the literature. Am J
Dent. 2014;27(2):63–7.
17. Chapple IL, Borgnakke WS, Genco RJ. Hemoglobin A1c levels
among patients with diabetes receiving nonsurgical periodontal
treatment. JAMA. 2014;311(18):1919–20.
18. Deschner J, Haak T, Jepsen S, Kocher T, Mehnert H, Meyle J, et al.
Diabetes mellitus and periodontitis. Bidirectional relationship and clin-
ical implications. A consensus document. Internist. 2011;52(4):466–77.
19. Bascones-Martinez A, Munoz-Corcuera M, Bascones-Ilundain J.
Diabetes and periodontitis: a bidirectional relationship. Med Clin.
2015;145(1):31–5.
20. Casanova L, Hughes FJ, Preshaw PM. Diabetes and periodontal
disease: a two-way relationship. Br Dent J. 2014;217(8):433–7.
21. Mealey B. Diabetes and periodontal diseases. J Periodontol.
1999;70(8):935–49.
22. Mirza W, Saleem MS, Patel G, Chacko P, Reddy S, Schaefer R,
et al. Early screening strategies for diabetes mellitus by leveraging
dental visits using optimal screening tools available onsite. Cureus.
2018;10(11):e3641.
23. Taylor GW, Borgnakke WS. Periodontal disease: associations with
diabetes, glycemic control and complications. Oral Dis. 2008;14(3):
191–203.
24. D'Aiuto F, Gkranias N, Bhowruth D, Khan T, Orlandi M, Suvan J,
et al. Systemic effects of periodontitis treatment in patients with
type 2 diabetes: a 12 month, single-centre, investigator-masked,
randomised trial. Lancet Diabetes Endocrinol. 2018;6(12):954–65.
25. TonettiMS,JepsenS, JinL,Otomo-Corgel J. Impactof theglobalburden
of periodontal diseases on health, nutrition and wellbeing of mankind: a
call for global action. J Clin Periodontol. 2017;44(5):456–62.
26. Listl S, Galloway J, Mossey PA, Marcenes W. Global economic
impact of dental diseases. J Dent Res. 2015;94(10):1355–61.
27. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M,
et al. Preferred reporting items for systematic review and meta-analysis
protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
28. Anders PL, Davis EL, McCall WD Jr. Dental students' glucometer
experience and attitudes toward diabetes counseling, monitoring, and
screening: a comparative study. J Dent Educ. 2014;78(9):1263–7.
29. Esmeili T, Ellison J, Walsh MM. Dentists' attitudes and practices
related to diabetes in the dental setting. J Public Health Dent. 70(2):
108–14.
30. Friman G, Hultin M, Nilsson GH, Wardh I. Medical screening in
dental settings: a qualitative study of the views of authorities and
organizations. BMC Res Notes. 2015;8:580.
31. Greenberg BL, Glick M, Frantsve-Hawley J, Kantor ML. Dentists'
attitudes toward chairside screening for medical conditions. J Am
Dent Assoc. 2010;141(1):52–62.
32. Greenberg BL, Kantor ML, Bednarsh H. American dental hygien-
ists' attitudes towards chairside medical screening in a dental set-
ting. Int J Dent Hyg. 2017;15(4):e61–e8.
33. Greenberg BL, Kantor ML, Jiang SS, Glick M. Patients' attitudes
toward screening for medical conditions in a dental setting. J Public
Health Dent. 2012;72(1):28–35.
34. Greenberg BL, Thomas PA, Glick M, Kantor ML. Physicians' atti-
tudes toward medical screening in a dental setting. J Public Health
Dent. 2015;11.
35. Greenblatt AP, Estrada I, Schrimshaw EW, Metcalf SS, Kunzel C,
Northridge ME. Acceptability of Chairside Screening for Racial/
Ethnic Minority Older Adults: A Qualitative Study. JDR Clin
Transl Res. 2017;2(4):343–52.
36. Sansare K, Raghav M, Kasbe A, Karjodkar F, Sharma N, Gupta A,
et al. Indian patients' attitudes towards chairside screening in a dental
setting for medical conditions. Int Dent J. 2015;65(5):269–76.
37. Scambler S, Asimakopoulou K. Summary of: Patients' attitudes
towards screening for diabetes and other medical conditions in the
dental setting. Br Dent J. 2014;216(1):34–5.
38. Rosedale MT, Strauss SM. Diabetes screening at the periodontal
visit: patient and provider experiences with two screening ap-
proaches. Int J Dent Hyg. 2012;10(4):250–8.
39. Creanor S, Millward BA, Demaine A, Price L, Smith W, Brown N,
et al. Patients' attitudes towards screening for diabetes and other
medical conditions in the dental setting. Br Dent J. 2014;216(1):E2.
40. Doherty R. Summary of: Patients' attitudes towards screening for
diabetes and other medical conditions in the dental setting. Br Dent
J. 2014;216(1):34–5.
41. Yonel Z, Sharma P, Yahyouche A, Jalal Z, Dietrich T, Chapple IL.
Patients’ attendance patterns to different healthcare settings and
perceptions of stakeholders regarding screening for chronic, non-
communicable diseases in high street dental practices and commu-
nity pharmacy: a cross-sectional study. BMJ Open. 2018;8(11).
42. Greenberg BL, Kantor ML, Bednarsh H. American dental hygien-
ists' attitudes towards chairside medical screening in a dental set-
ting. Int J Dent Hyg. 2016;28:28.
43. Bossart M, Calley KH, Gurenlian JR, Mason B, Ferguson RE,
Peterson T. A pilot study of an HbA1c chairside screening protocol
for diabetes in patients with chronic periodontitis: the dental hy-
gienist's role. Int J Dent Hyg. 2015;23.
44. Bould K, Scott SE, Dunne S, Asimakopoulou K. Uptake of screen-
ing for type 2 diabetes risk in general dental practice; an exploratory
study. Bdj. 2017;222:293.
45. Engstrom S, Berne C, Gahnberg L, Svardsudd K. Effectiveness of
screening for diabetes mellitus in dental health care. Diabet Med.
2013;30(2):239–45.
46. Barasch A, Gilbert GH, Spurlock N, Funkhouser E, Persson L-L,
Safford MM, et al. Random plasma glucose values measured in
community dental practices: findings from the dental practice-
based research network. Texas Dent J. 2013;130(4):291–7.
47. NICE. Type 2 diabetes: prevention in people at high risk. NiCE:
National Institute for Health and Care Excellence, updated 2017.
48. van den Donk M, Sandbaek A, Borch-Johnsen K, Lauritzen T,
Simmons RK, Wareham NJ, et al. Screening for type 2 diabetes.
Lessons from the ADDITION-Europe study. Diabet Med.
2011;28(11):1416–24.
49. Penn L, Rodrigues A, Haste A, Marques MM, Budig K, Sainsbury
K, et al. NHS diabetes prevention Programme in England: forma-
tive evaluation of the programme in early phase implementation.
BMJ Open. 2018;8(2):e019467.
50. Arrendale JR, Cherian SE, Zineh I, Chirico MJ, Taylor JR.
Assessment of glycated hemoglobin using A1CNow+ point-of-
care device as compared to central laboratory testing. J Diabetes
Sci Technol. 2008;2(5):822–7.
51. Ardakani MR, Moeintaghavi A, Haerian A, Ardakani MA,
Hashemzadeh M. Correlation between levels of sulcular and capil-
lary blood glucose. J Contemp Dent Pract. 2009;10(2):10–7.
52. Khader YS, Al-Zu'bi BN, Judeh A, RayyanM. Screening for type 2
diabetes mellitus using gingival crevicular blood. Int J Dent Hyg.
2006;4(4):179–82.
53. Rajesh KS, Irshana R, Kumar MSA, Hegde S. Effectiveness of
glucometer in screening diabetes mellitus using gingival crevicular
blood. Contemp Clin Dent. 2016;7(2):182–5.
54. Sibyl S, Bennadi D, Kshetrimayum N, Manjunath M. Correlations
between gingival crevicular blood glucose and capillary blood glu-
cose: a preliminary report. J Lab Physicians. 2017;9(4):260–3.
55. Muller HP, Behbehani E. Screening of elevated glucose levels in
gingival crevice blood using a novel, sensitive self-monitoring de-
vice. Med Princ Pract. 2004;13(6):361–5.
Publisher’s Note Springer Nature remains neutral with regard to juris-
dictional claims in published maps and institutional affiliations.
Curr Oral Health Rep
